Kiniksa Pharmaceuticals International (KNSA) Finished Goods (2021 - 2023)

Kiniksa Pharmaceuticals International has reported Finished Goods for 3 years, with the latest figure at $12.9 million in Q4 2023.

• For the quarter ending Q4 2023, Finished Goods fell 15.85% year-over-year to $12.9 million; the trailing twelve-month figure through Dec 2023 stood at $12.9 million (down 15.85% YoY), and the FY2023 full-year result was $12.9 million, down 15.85% from the prior year.
• Finished Goods for Q4 2023 stood at $12.9 million, up from $12.2 million in the prior quarter.
• The five-year high for Finished Goods was $19.9 million in Q2 2022, with the low at $1.4 million in Q3 2021.
• Historically, Finished Goods has averaged $10.4 million across 3 years, with a median of $12.5 million in 2023.
• Annual changes were most pronounced in 2022 — Finished Goods jumped 927.48% — and 2023, when it dropped 24.22%.
• Kiniksa Pharmaceuticals International's Finished Goods stood at $3.7 million in 2021, then surged by 315.97% to $15.3 million in 2022, then retreated by 15.85% to $12.9 million in 2023.
• The last three Finished Goods figures came in at $12.9 million (Q4 2023), $12.2 million (Q3 2023), and $17.3 million (Q2 2023), per Business Quant data.